China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SAN FRANCISCO, Aug. 15, 2017 -- NGX Bio, Inc., (www.NGXbio.com) the premier marketplace for online DNA sequencing services, announced it has closed a $3 million funding round. The round was led by 180 Degree Capital Corp. (NASDAQ:TURN) and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors.
NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally. Demand for sequencing services is growing exponentially. NGX Bio’s platform matches the sequencing needs of customers with providers who have available sequencing capacity. Customers are able to purchase a wide range of sequencing services for their samples using NGX Bio’s online ordering tools. NGX Bio offers these services through numerous and deep relationships with its extensive network of sequencing service providers. The ability to offer virtually unlimited sequencing capacity, to finish projects rapidly, and to always stay at the cutting edge of fast-evolving sequencing technologies distinguishes NGX Bio from its competitors and from internal corporate, academic or government sequencing resources.
“We appreciate the support from our investors to fund the next stage of the growth of our business,” said Denis Kourakin, President and Chief Executive Officer of NGX Bio. “Our platform makes completion of sequencing projects simpler and more affordable for all clients and allows them to scale without the need for capital investment. This funding will allow us to continue our relentless focus on delivering high-quality, rapid and cost-effective sequencing solutions for our customers."
About NGX Bio:
NGX Bio is a San Francisco-based company providing streamlined, on-line access to next generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing solutions globally. Founded in 2014 by two professors of Stanford University, NGX Bio offers virtually unlimited sequencing capacity to its customers through its partnerships with numerous sequencing providers.
Contact: Denis Kourakin Phone: +1 (415) 464 6379 e-mail: [email protected]
